This browser doesn't support Spotify Web Player. Switch browsers or download Spotify for your desktop.

Audio Journal of Oncology Podcast

By Audio Medica News

As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoken comments on the clinical implications of cancer developments in the real-world context, as practiced by cancer doctors and clinicians around the globe. The AJO Podcast originates from the Audio Journal of Oncology—staffed by ex-BBC professional journalists, and mentored by world-leading cancer practitioners from bodies including the American Society of Clinical Oncology, Cancer Research UK, Istituto Nazionale dei Tumori, and Action Radiotherapy. Each podcast is produced to the highest standards of audio recording and journalism and is subject to editorial appraisal to maintain that content, balance and clinical relevance of news and comment are delivered in a manner that's easy and enjoyable for listening while travelling, taking exercise, working or just relaxing. Please contact Audio Medica with your comments and make your contribution to supporting a vibrant community of clinical cancer communicators!

  1. 1.
    Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent02/07/2020
    16:38
  2. 2.
    New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia01/24/2020
    2:28
  3. 3.
    Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation01/14/2020
    11:28
  4. 4.
    Genomic-led AML Clinical Decision Making Within Seven Days12/31/2019
    10:30
  5. 5.
    Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?10/07/2019
    9:59
  6. 6.
    Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”11/12/2018
    4:56
  7. 7.
    Which New Combination for Metastatic Renal Cell Cancer?11/12/2018
    7:08
  8. 8.
    Two Drug Combination Doubled Kidney Cancer Progression Free Survival11/07/2018
    10:43
  1. 9.
    ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 11/07/2018
    9:26
  2. 10.
    First Line PARP Inhibition For Ovarian Cancer Assessed11/02/2018
    7:39
  3. 11.
    BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib11/01/2018
    9:50
  4. 12.
    PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression10/31/2018
    6:30
  5. 13.
    Genomically Targeted Therapy Delays Advanced Breast Cancer Progression10/31/2018
    6:47
  6. 14.
    Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy10/29/2018
    5:29
  7. 15.
    Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer10/27/2018
    6:39
  8. 16.
    Pembrolizumab: No Survival Gains Second Line In Gastric Cancer10/18/2018
    6:54
  9. 17.
    Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib10/15/2018
    8:30
  10. 18.
    Trifluridine with Tipiracil Lifts Survival in Refractory Gastric Cancer10/11/2018
    12:11
  11. 19.
    Esophageal Cancer Prevented By Proton Pump Inhibitor Plus Aspirin08/15/2018
    8:54
  12. 20.
    Preoperative Chemoradiotherapy Extends Survival in Pancreatic Cancer07/25/2018
    5:52
  13. 21.
    Whole Genome Sampling Identifies Targetable Prostate Cancer Subgoups07/20/2018
    7:04
  14. 22.
    Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer07/18/2018
    9:43
  15. 23.
    Superior Survival in Conservatively Treated Male Breast Cancer07/13/2018
    6:01
  16. 24.
    Gender Disparity in Head and Neck Cancer Treatment and Outcomes06/09/2018
    7:57
  17. 25.
    Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer06/08/2018
    13:41
  18. 26.
    Radiotherapy Cuts BRCA-Associated Contralateral Breast Cancer Risk06/07/2018
    6:41
  19. 27.
    Handgrip Strength Predicts Survival in Elderly Patients with Lung Cancer05/29/2018
    10:22
  20. 28.
    Brachytherapy “Excellent” After Breast Conserving Surgery05/23/2018
    13:20
  21. 29.
    Cervical Cancer: No Ureteral Stricture Increase With IG Brachytherapy05/23/2018
    22:04
  22. 30.
    Lung Cancer: Geriatric Assessment Before Concurrent Chemo-Radiotherapy05/22/2018
    13:57
  23. 31.
    Image-Guided Radiotherapy: Positioning Errors Affect Overall Survival05/18/2018
    8:16
  24. 32.
    Breast Lumps Between Mammography Visits Signal High Risk04/19/2018
    6:38
  25. 33.
    Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer04/18/2018
    7:59
  26. 34.
    Reassurance on Ductal Carcinoma in Situ (DCIS) Treatment De-Escalation04/17/2018
    6:43
  27. 35.
    Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation04/16/2018
    13:08
  28. 36.
    Double Mastectomy: No Survival Gain for BRCA2 Mutation Carriers—AUDIO JOURNAL OF ONCOLOGY03/30/2018
    4:55
  29. 37.
    Polygenic Risk Scores Could Help Predict Second Primary Breast Cancers—AUDIO JOURNAL OF ONCOLOGY03/28/2018
    4:29
  30. 38.
    Randomized Study Confirms Rivaroxaban Oral Alternative For Cancer Thromboembolism02/05/2018
    15:28
  31. 39.
    Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism02/05/2018
    15:28
  32. 40.
    Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism01/26/2018
    9:39
  33. 41.
    Venetoclax Pro-Apoptotic Therapy Benefits Older Patients with Acute Myeloid Leukemia01/19/2018
    4:57
  34. 42.
    Cabozantinib Better for VEGF Resistant Metastatic Renal Cell Carcinoma04/20/2017
    5:54
  35. 43.
    Which High-Risk Prostate Cancers Need Multimodality Treatment?04/18/2017
    14:03
  36. 44.
    Women With DCIS Live Longer Than General Population03/12/2017
    5:33
  37. 45.
    First-Line Pembrolizumab Boosts Survival in PD-L1-Positive Advanced Lung Cancer01/02/2017
    11:28
  38. 46.
    Second-Generation ALK Inhibitor = Longer PFS in ALK+ Lung Cancer After Crizotinib12/08/2016
    8:52
  39. 47.
    PD-L1 Checkpoint Inhibitor Immunotherapy Boosts Survival in Lung Cancer12/06/2016
    10:30
  40. 48.
    Lung Cancer—First-Line Checkpoint Inhibitor Combination Benefit11/23/2016
    12:08
  41. 49.
    Early Lung Cancer Responds to Preoperative Nivolumab11/17/2016
    12:59
  42. 50.
    Vantictumab Combination Benefits Patients with Stage IV Pancreatic Cancer10/31/2016
    9:28

Listen to Audio Journal of Oncology Podcast now.

Listen to Audio Journal of Oncology Podcast in full in the Spotify app